PCCA: The Ingredient Came With a Reimbursement Pitch

The PCCA compounding ingredient AWP complaint alleged that the supplier inflated reported ingredient prices and used the resulting reimbursement margins to win pharmacy customers. The pharmacies bought the ingredients, put them into compounded prescriptions and billed TRICARE. The government’s accusation reached back to the supplier that set the price benchmark and promoted the profit it could produce.

Professional Compounding Centers of America, known as PCCA, is a Houston-based supplier to compounding pharmacies. The Justice Department announced its complaint on November 8, 2021, joining a pharmaceutical fraud case brought by a pharmacist who had worked at and partly owned a customer pharmacy. The government alleged a pricing and sales scheme running from at least March 2012 through May 2015.

The Ingredient Price and the Reported AWP

PCCA’s reported average wholesale prices allegedly bore no rational relationship to what its customers actually paid. The government’s complaint gives a concrete comparison: in 2014, PCCA frequently sold fluticasone propionate to certain pharmacy customers for approximately $135 to $197 per gram while reporting an average wholesale price of about $3,631 per gram. For resveratrol, the alleged selling price to certain customers was under $2 per gram, against a reported average wholesale price of about $819. The government described that reported price as more than 400 times the actual selling price.

The reported average wholesale price helped determine what TRICARE would reimburse for a prescription containing the ingredient. The complaint alleged that PCCA controlled both numbers and knew its customers valued the difference.

That is the commercial attraction behind the alleged compounding ingredient AWP fraud. A supplier could make its product attractive by offering a large reimbursement opportunity to the pharmacy buying it. In the government’s account, the ingredient and the margin were being sold together.

The supply relationship made that pitch practical. PCCA bought active pharmaceutical ingredients from chemical and ingredient manufacturers, repackaged them and resold them to pharmacies. It also sold cream and gel bases into which pharmacists added those ingredients. For the ingredients and bases it sold, PCCA generally reported an average wholesale price to commercial drug-price publishers. The supplier selling the materials also supplied a number that helped price the finished prescription’s claim.

The Sales Pitch Answered a Price Complaint

The government alleged that inflated average wholesale prices let PCCA charge more than competitors and answer customer complaints about those prices by emphasizing greater reimbursement. A higher invoice could be sold as a better business opportunity because the pharmacy expected a still larger payment from the health care program.

The complaint put the alleged purpose plainly:

According to the complaint, senior management instructed sales representatives to highlight the gap between reported average wholesale prices and selling prices.

The alleged inducements extended beyond price reporting. The government said PCCA rewarded top customers with annual all-inclusive travel packages. It also alleged that PCCA advised pharmacies on third-party billing, business growth, profitability goals and maximizing reimbursement for compound prescriptions.

Formula support was part of that allegation. The complaint said PCCA identified and promoted compound-drug formulas designed to maximize pharmacy reimbursement. For someone working with those formulas, the question is what drove their promotion: the government’s case connected the ingredient choice, the reimbursement advice and the supplier’s sales interest.

Why a Supplier’s Benchmark Could Move a Pharmacy’s Payment

Average wholesale price was a published benchmark that could diverge sharply from actual transaction prices. A federal court’s 2007 average wholesale price trial findings described reported prices that pharmacies and physicians rarely, if ever, paid. The broader average wholesale price fraud pattern depended on that gap becoming something a seller could market.

The Department of Health and Human Services’ inspector general explained the incentive in its 2003 compliance guidance for pharmaceutical manufacturers. A seller that controls the spread can control its customer’s profit. The guidance treated deliberately inflating the price and selling the gap as a sign of a kickback. The financial benefit comes from the government payment to the customer, giving the supplier a way to reward purchases through the public program’s bill.

The government’s complaint against PCCA applied that logic to compound ingredients. It alleged that PCCA knew pharmacies would submit claims using its ingredients and that its reported average wholesale prices affected their reimbursement. The pharmacies submitted the claims, while the supplier allegedly shaped the numbers and incentives behind them. The government alleged tens of thousands of affected compound prescription claims and hundreds of millions of dollars in excess TRICARE reimbursement.

TRICARE serves active duty military personnel, military retirees and military dependents. The military’s health care program allegedly paid for the margin behind the supplier’s sales pitch.

An Old Pricing Problem in a Different Supply Chain

Public Citizen’s 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, found that overcharging government health programs appeared in more settlements than any other violation category. Much of that history involved state Medicaid programs relying on falsely elevated average wholesale prices. The report also described the move toward reimbursement based on actual acquisition costs as a change that could reduce average wholesale price fraud.

Here the reported prices attached to ingredients used in compounded prescriptions, and the government identified TRICARE as the payer.

Other Ingredient Suppliers Faced the Same Pricing Allegation

Fagron Holding USA agreed to a $22.05 million settlement announced in November 2019. Its subsidiary Freedom Pharmaceuticals allegedly inflated ingredient benchmarks and marketed reimbursement spreads to pharmacies billing TRICARE and federal workers’ compensation. Fluticasone was among its ingredients too.

Medisca agreed to a $21.75 million settlement announced in November 2024 over alleged inflated average wholesale prices for resveratrol and mometasone furoate used by pharmacies billing those programs. These separate settlements show why an ingredient supplier’s reported price can matter well beyond its own invoice. The pharmacy’s reimbursement opportunity was part of the transaction the government examined.

The neighboring wholesaler case followed a different route to the same kind of benchmark. The government alleged that McKesson reported inflated markup percentages to First DataBank, which published average wholesale prices used by Medicaid. PCCA’s complaint instead concerned the ingredient supplier’s own reported prices and its direct pitch to compounding pharmacies.

Can a Pharmacist Be a Whistleblower?

Yes. The PCCA case began with a pharmacist who had worked at and partly owned a compounding pharmacy that bought ingredients and services from the supplier.

That perspective matters. A pharmacy customer can see both what an ingredient costs and what the supplier says about billing for it. The person with useful knowledge may be on the receiving end of the sales pitch, with direct experience of the purchasing and reimbursement relationship.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What Evidence Is Needed to Prove Fraud?

What proves an ingredient-pricing case is something our whistleblower experts work through with the insider. The government’s complaint against PCCA connected the supplier’s price reports and sales instructions to the pharmacies’ reimbursement claims. We examine that relationship with you, including what the supplier told customers about formulas and billing.

A supplier pricing employee may know how the reported benchmark was selected. A salesperson may know what management wanted customers told. A pharmacy purchaser or billing employee may recognize the same promise in the supplier’s advice and the resulting claims. Those different views help explain how a number reported upstream became a healthcare payment downstream.

You Know How the Ingredient Was Sold

Speak to one of our whistleblower experts about how the ingredient was priced and sold. We work with you to build your strongest pharmaceutical whistleblower case and bring in whistleblower lawyers who understand compounding ingredient pricing and government reimbursement. We stay beside you as the case moves from what you saw inside the business to the pursuit of a recovery.